Wet Heparinized Suction for Abdominal Cancer (EUS Heparin)
Cancer of Pancreas, Cancer of Stomach, Cancer of Esophagus
About this trial
This is an interventional diagnostic trial for Cancer of Pancreas focused on measuring cancer, esophagus, stomach, gastric, pancreas, biliary, bile, bile duct, liver, hepatic
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 year
- Non-pregnant Patients
- Patients with the presence of a solid abdominal mass as seen on diagnostic imaging [ie. ultrasound (US), computer tomography (CT) or magnetic resonance imaging (MRI)] scheduled to undergo EUS examination OR Patients who underwent a prior EUS-FNA/FNB for solid pancreatic mass and did not receive a conclusive diagnosis
- Patients with platelet count > 50,000
- Patients with International Normalized Ratio (INR) < 1.5
Exclusion Criteria:
- Age < 18 years
- Pregnant Patients
- Patients who cannot consent for themselves
- Patients with anticoagulants or anti-platelet agents (excluding aspirin) within the last 7-10 days
- Patients with cystic abdominal masses
- Patients with a platelet count < 50,000
- Patients with an INR > 1.5
- Patients with a heparin or porcine allergy
- Patients with prior heparin induced thrombocytopenia (HIT)
- Patient's with religious aversion to porcine-containing products
Sites / Locations
- Moffitt Cancer Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Active Comparator
Heparin and microsieve
Heparin and no microsieve
No heparin and microsieve
No heparina nd no microsieve
The needle will be prepped with 500 U heparin USP per 10 mL to coat the inside of the needle. The provider will expel the tissue onto the microsieve
The needle will be prepped with 500 U heparin USP per 10 mL to coat the inside of the needle. The provider will expel the tissue into formalin
The needle not be prepped. The provider will expel the tissue onto the microsieve
The needle not be prepped. The provider will expel the tissue into formalin